Heghine Khachatryan: When to Consider Ehlers–Danlos Syndromes in Patients with Bleeding Symptoms?
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared European Association for Haemophilia and Allied Disorders (EAHAD)’s post on LinkedIn, adding:
”When Should We Consider Ehlers–Danlos Syndromes in Patients with Bleeding Symptoms?
Connective tissue disorders, particularly Ehlers–Danlos Syndromes (EDS), remain under-recognized in daily hematology practice — yet they frequently present with hemorrhagic manifestations that may mimic primary hemostatic disorders.
The newly released EAHAD e-learning module (Module 21) provides valuable clinical insight into:
- Recognizing red flags in patients with unexplained bleeding
- Understanding the overlap between connective tissue fragility and hemostatic abnormalities
- Improving multidisciplinary diagnostic pathways
- Avoiding misdiagnosis of inherited bleeding disorders
As clinicians working in benign hematology and hemostasis, it is essential that we broaden our differential diagnosis when laboratory results do not fully explain the clinical phenotype.
Timely identification of EDS can significantly impact patient management, perioperative planning, and long-term follow-up.
I strongly encourage colleagues involved in bleeding disorders, women’s health, and rare disease diagnostics to explore this educational resource.”
Quoting European Association for Haemophilia and Allied Disorders (EAHAD)’s post:
”Don’t miss our e-learning module on the Ehlers-Danlos Syndromes (EDS), rare, inherited multisystemic connective tissue disorders frequently associated with bleeding symptoms and haematological challenges.”
Proceed to the video attached to the post.
Find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis